• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial.

作者信息

Fan Yujuan, Xia Mingfeng, Yan Hongmei, Li Xiaoying, Chang Xinxia

机构信息

Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.

Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, Shanghai, China.

出版信息

Diabetes Obes Metab. 2024 Feb;26(2):772-776. doi: 10.1111/dom.15359. Epub 2023 Nov 17.

DOI:10.1111/dom.15359
PMID:37975640
Abstract
摘要

相似文献

1
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial.贝那鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病患者肝脂肪变性的疗效：一项随机、开放标签、对照试验。
Diabetes Obes Metab. 2024 Feb;26(2):772-776. doi: 10.1111/dom.15359. Epub 2023 Nov 17.
2
Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。
Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.
3
Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.贝那鲁肽在 ob/ob 肥胖型糖尿病/肥胖型非酒精性脂肪性肝炎小鼠模型中显示出显著的有益作用。
Life Sci. 2021 Apr 1;270:118966. doi: 10.1016/j.lfs.2020.118966. Epub 2021 Jan 19.
4
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.一项评估 efinopegdutide 在非酒精性脂肪性肝病患者中的疗效和安全性的 IIa 期主动对照研究。
J Hepatol. 2023 Oct;79(4):888-897. doi: 10.1016/j.jhep.2023.05.013. Epub 2023 Jun 22.
5
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.评估钠-葡萄糖共转运蛋白 2 抑制剂达格列净对 2 型糖尿病合并非酒精性脂肪性肝病患者肝脂肪变性和纤维化的影响：应用瞬时弹性成像技术。
Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2.
6
Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.用于2型糖尿病合并非酒精性脂肪性肝病患者的抗糖尿病药物：来自随机对照试验网络荟萃分析的证据
Endocr Pract. 2022 Feb;28(2):223-230. doi: 10.1016/j.eprac.2021.09.013. Epub 2021 Oct 1.
7
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).2 型糖尿病伴非酒精性脂肪性肝病的胰高血糖素样肽 1 受体激动剂（GLP1-RA）作用的荟萃分析。
Sci Rep. 2021 Nov 11;11(1):22063. doi: 10.1038/s41598-021-01663-y.
8
Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: A randomized, placebo-controlled trial.二醋酸姜黄素在 2 型糖尿病合并非酒精性脂肪性肝病患者中减少肝脂肪变性和纤维化的疗效：一项随机、安慰剂对照试验。
Diabetes Obes Metab. 2019 May;21(5):1266-1270. doi: 10.1111/dom.13643. Epub 2019 Mar 4.
9
Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.比较 2 型糖尿病患者抗糖尿病药物对非酒精性脂肪性肝病的疗效：随机和非随机研究的系统评价和荟萃分析。
Diabetes Metab Res Rev. 2016 Feb;32(2):200-16. doi: 10.1002/dmrr.2713. Epub 2015 Nov 1.
10
Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.胰高血糖素样肽-1 受体激动剂在非酒精性脂肪性肝病中的治疗机制和临床疗效。
Int J Mol Sci. 2023 May 26;24(11):9324. doi: 10.3390/ijms24119324.

引用本文的文献

1
Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis.每日三次注射的胰高血糖素样肽-1（GLP-1）受体激动剂贝那鲁肽对体重和代谢参数的影响：一项系统评价和荟萃分析。
World J Diabetes. 2025 May 15;16(5):103244. doi: 10.4239/wjd.v16.i5.103244.
2
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.代谢功能障碍相关脂肪性肝病：分子机制、临床意义及新兴治疗策略
Int J Mol Sci. 2025 Mar 25;26(7):2959. doi: 10.3390/ijms26072959.
3
Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.
与胰高血糖素样肽-1受体激动剂相关的代谢功能障碍相关脂肪性肝病（MASLD）的胃肠道不良事件：一项系统评价和荟萃分析。
Front Med (Lausanne). 2025 Feb 20;12:1509947. doi: 10.3389/fmed.2025.1509947. eCollection 2025.
4
Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.胰高血糖素样肽-1受体激动剂在代谢功能障碍相关脂肪性肝病中的现状：临床视角
J Clin Transl Hepatol. 2025 Jan 28;13(1):47-61. doi: 10.14218/JCTH.2024.00271. Epub 2024 Nov 6.